



Content highlights

Release date

2023

Updated annually to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, Europe

Primary research

Survey of over 540 physicians in the United States and Europe from six specialties:

gastroenterologist, endocrinologists, nephrologists, rheumatologists, medical oncologists, and hematologist-oncologists.

Key drugs covered

Admelog/Insulin Lispro
Sanofi, Avastin, Enbrel, Herceptin, Herzuma, Hulio, Humira, Inflectra, Kanjinti, Lantus, Mvasi, Neulasta, Nivestim/Nivestym, Remicade, Rituxan/MabThera, Semglee, Truxima, Udenyca.

Key insights provided

Factors influencing disease management and treatment decisions

Physician-reported treatment practices and brand-level patient shares

Biosimilars

Spotlight on U.S. and European Current Treatment: Physician Insights

Market outlook

As the biosimilar space becomes increasingly competitive, it is important that manufacturers and marketers of biosimilars and branded biologics understand the factors that most influence physicians' choice of therapy. Understanding physicians' attitude and behavior toward biosimilars is critical for development and marketing strategies aimed at convincing physicians to prescribe and drive biosimilar uptake. Clarivate's primary research with physicians across multiple specialties (oncologists, rheumatologists, gastroenterologists, nephrologists, and endocrinologists) in the United States and Europe allows us to assess the dynamics determining current and future biosimilar uptake.

Questions answered

- How do physicians perceive currently available biosimilars, where available?
- Which types of biosimilar manufacturers do physicians trust most?
- How will physicians choose between multiple biosimilars of the same reference product?
- What are the current levels of experience in prescribing biosimilars in different specialties?
- How will physicians adopt biosimilars initially, and will adoption vary by specialty?
- What are the greatest drivers of/barriers to biosimilar use?
- How familiar with biosimilars are physicians in different specialties?
- Are physicians aware of the pharmacy-level substitution rules in their own country, and would they expect to prevent this substitution?

Product description

Clarivate's Biosimilars | Current Treatment offerings provides physician insights on treatment dynamics, prescribing behavior, and drivers of biosimilar use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position. *Current Treatment* also provides deep-dives into the therapy areas of *Endocrinology*, *Immunology*, *Nephrology*, and *Oncology*.

Solution enhancement

Interactive target product profiles for oncology and immunology allows customers to quantify how physicians choose between multiple biosimilars of a given reference product based on specific attributes (including price).

Learn more about Clarivate's full suite of Biosimilars solutions:

DRG.support@clarivate.com | clarivate.com